Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 1/2 1

Status

Completed 9Active not recruiting 5Unknown 2Recruiting 2Withdrawn 1

Sponsor Class

OTHER 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Prostatic Neoplasms 5Neoplasm Metastasis 1Metastatic Castration-resistant Prostate Cancer 1Biochemical Recurrent Prostate Cancer 1

Interventions

enzalutamide 33Abiraterone Acetate 28apalutamide 25Radiotherapy 25Prednisone 25Magnetic Resonance Spectroscopy 25Androgen Antagonists 24Leuprolide 21Radiosurgery 19darolutamide 18Docetaxel 17acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Gonadotropin-Releasing Hormone 14gallium 68 PSMA-11 12Specimen Handling 12Goserelin 12pembrolizumab 11Radiotherapy, Intensity-Modulated 11Radiation 11bicalutamide 10abiraterone 10Pluvicto 10Carboplatin 9Brachytherapy 92-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 9relugolix 8luprolide acetate gel depot 8Standard of Care 8Nivolumab 8olaparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × Radium-223 × Clear all
NCT03574571 2026-05-14

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Memorial Sloan Kettering Cancer Center

Phase 3 Active not recruiting
732 enrolled
Genitourinary

Prostatic Neoplasms

NCT05924672 2026-01-14

Efficacy of Ra-223 in PSMA PET Optimally Selected Patients

University of California, San Francisco

Phase 2 Active not recruiting
2 enrolled
Genitourinary

Prostatic Neoplasms

NCT02194842 2025-09-19

PEACE III

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Active not recruiting
446 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

NCT05383079 2025-02-07

AlphaBet

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Active not recruiting
36 enrolled
Genitourinary

Prostatic Neoplasms

NCT03230734 2024-09-27

RAPSON

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

Phase 2 Active not recruiting
70 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡